Ginkgo Bioworks Holdings, Inc. $DNA Shares Purchased by UBS Group AG

UBS Group AG grew its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 86.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 489,418 shares of the company’s stock after acquiring an additional 226,861 shares during the period. UBS Group AG’s holdings in Ginkgo Bioworks were worth $4,067,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in shares of Ginkgo Bioworks during the 2nd quarter worth about $29,000. Quarry LP bought a new stake in shares of Ginkgo Bioworks during the 3rd quarter worth about $29,000. Strs Ohio bought a new stake in shares of Ginkgo Bioworks during the 3rd quarter worth about $44,000. Daiwa Securities Group Inc. bought a new stake in shares of Ginkgo Bioworks during the 2nd quarter worth about $71,000. Finally, State of Wyoming bought a new stake in shares of Ginkgo Bioworks during the 3rd quarter worth about $74,000. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Price Performance

NYSE DNA opened at $8.42 on Friday. The company’s 50 day simple moving average is $7.51 and its 200 day simple moving average is $8.41. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.37 and a 12 month high of $17.58. The company has a market capitalization of $549.80 million, a P/E ratio of -1.57 and a beta of 1.77.

Ginkgo Bioworks (NYSE:DNA) last released its earnings results on Thursday, February 26th. The company reported ($1.42) EPS for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.38. Ginkgo Bioworks had a negative net margin of 215.41% and a negative return on equity of 56.08%. The business had revenue of $33.40 million for the quarter, compared to the consensus estimate of $37.57 million.

Insider Buying and Selling at Ginkgo Bioworks

In related news, insider Jason R. Kelly sold 109,767 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $6.40, for a total value of $702,508.80. Following the sale, the insider directly owned 316,483 shares in the company, valued at $2,025,491.20. The trade was a 25.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Reshma P. Shetty sold 124,727 shares of the business’s stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $6.43, for a total transaction of $801,994.61. Following the completion of the sale, the insider owned 436,422 shares in the company, valued at $2,806,193.46. The trade was a 22.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 542,981 shares of company stock valued at $3,548,999 over the last quarter. Company insiders own 12.69% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on DNA. Weiss Ratings restated a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Monday, April 20th. Wall Street Zen downgraded shares of Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, BTIG Research dropped their price target on shares of Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating on the stock in a research report on Thursday, March 12th. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $8.50.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.